Andrew Pettitt
Overview
Explore the profile of Andrew Pettitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carr L, Norris K, Parker H, Nilsson-Takeuchi A, Bryant D, Amarasinghe H, et al.
Br J Haematol
. 2024 Sep;
205(5):2072-2076.
PMID: 39253978
No abstract available.
2.
Popa M, Young B, Rousseau N, Cherry M, Jenkins I, Cloke J, et al.
Trials
. 2024 Jun;
25(1):382.
PMID: 38872208
Background: Patients from socioeconomically disadvantaged backgrounds are underserved in randomised controlled trials, yet they experience a much greater burden of disease compared with patients from socioeconomically advantaged areas. It is...
3.
Lim Y, Ward V, Brown A, Phillips E, Kronsteiner B, Malone T, et al.
Br J Haematol
. 2024 Jun;
205(2):440-451.
PMID: 38867615
Immune responses to primary COVID-19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016-004010-10). COVID-19 vaccines (BNT162b2 or...
4.
Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al.
N Engl J Med
. 2023 Dec;
390(4):326-337.
PMID: 38078508
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment...
5.
Lin W, Fordham S, Sunter N, Elstob C, Rahman T, Willmore E, et al.
Nat Commun
. 2021 Jan;
12(1):665.
PMID: 33510140
Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognostication. Pooling...
6.
Bhogal T, Khan U, Lee R, Stockdale A, Hesford C, Potti-Dhananjaya V, et al.
Leuk Lymphoma
. 2021 Jan;
62(7):1682-1691.
PMID: 33508995
The COVID-19 pandemic has been a disruptive event for cancer patients, especially those with haematological malignancies (HM). They may experience a more severe clinical course due to impaired immune responses....
7.
Khan U, Kelly M, Dodd J, Fergiani S, Hammer B, Smith J, et al.
J Clin Pathol
. 2020 Dec;
74(12):816-818.
PMID: 33380460
No abstract available.
8.
Offner F, Robak T, Janssens A, Govind Babu K, Kloczko J, Grosicki S, et al.
Br J Haematol
. 2020 Apr;
190(5):736-740.
PMID: 32236950
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the...
9.
Eyre T, Hildyard C, Hamblin A, Ali A, Houlton A, Hopkins L, et al.
Hematol Oncol
. 2019 Aug;
37(4):352-359.
PMID: 31385336
Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are unfit for or relapsed postautologous stem-cell transplantation have poor outcomes. Historically, mTORC1 inhibitors have produced responses in approximately...
10.
Hillmen P, Rawstron A, Brock K, Munoz-Vicente S, Yates F, Bishop R, et al.
J Clin Oncol
. 2019 Jul;
37(30):2722-2729.
PMID: 31295041
Purpose: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and...